ArticleOpen forum infectious diseases2024
Epidemiology, Risk Factors, and Prophylaxis Use for
Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Outcomes of concomitantAnnals of medicine · 2026Article
- Prophylaxis Regimens forJournal of fungi (Basel, Switzerland) · 2026Review
- Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer.Breast cancer research and treatment · 2026Article
- Combined Serum (1,3)-β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection ofOpen forum infectious diseases · 2026Article
- Construction of a Diagnostic Model for Pneumocystis Jirovecii Pneumonia in HIV-Negative Patients Based on Single-Center Patient Data.Infection and drug resistance · 2026Article
- Pneumocystis pneumonia in older non-HIV-infected patients: a French, multicentre, retrospective, cohort study.Pneumonia (Nathan Qld.) · 2025Article
- Review
- Experimental Pneumocystis infection in dexamethasone immunosuppressed macaques.Medical mycology · 2025Article
- An Observational Analysis of a Large Cohort ofOpen forum infectious diseases · 2025Article
- Epidemiology and Clinical Relevance ofJournal of clinical medicine · 2025Article
- Efficacy and Safety of Low-Dose Trimethoprim-Sulfamethoxazole (TMP-SMZ) for the Prevention ofInfection and drug resistance · 2025Article
- Protective efficacy of a 'pan-fungal' vaccination strategy against experimentalFrontiers in immunology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: In this multicenter retrospective trial, all non-HIV adult cases admitted to hospitals in Québec City, Canada, between January 2011 and January 2021 with a diagnosis of PJP were assessed for eligibility. Results: An overall 129 cases of PJP were included. More than two-thirds had an underlying hematologic disease or an autoimmune/inflammatory condition. Prior to diagnosis, 83.7% were taking corticosteroids, 71.3% immunosuppressive agents (alone or in combination with corticosteroids), and 62% both. A diagnosis of PJP was noted in 22 patients receiving corticosteroids for treatment <28 days. Two patients developed PJP while undergoing corticosteroid monotherapy at a mean daily prednisone-equivalent dose <20 mg/d; 4.7% of our cohort received a PJP prophylaxis. Current recommendations or accepted clinical practices for PJP prophylaxis would not have applied to 48.8% of our patients. Conclusions: The use of corticosteroids-in monotherapy or in coadministration with other immunosuppressive agents-remains the principal risk factor for PJP in the non-HIV population. Current prophylaxis guidelines and accepted practices are insufficient to adequately prevent PJP and need to be broadened and updated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.